Loading clinical trials...

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects

NCT00134199•Pfizer

View on ClinicalTrials.gov

Summary

To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-Î± and hsCRP * the relationship between the concentration of the drug on the blood and the above parameters * physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and/or female subjects without clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12 lead ECG and clinical laboratory tests
•Body Mass Index (BMI) Â³30 and \<40 kg/m2, for subjects with no additional
•co morbidities; BMI Â³27 kg/m2 and \<40 kg/m2, for subjects with co morbidities \[history of essential hypertension and/or dyslipidemia defined as high LDL (Â³160 mg/dL) or high total cholesterol (Â³240 mg/dL)\];

Exclusion Criteria

•Subjects with resting sitting systolic blood pressure of 140 mmHg or greater or diastolic blood pressure of 90 mmHg or greater.
•Subjects with type 2 diabetes or fasting blood glucose concentration Â³126 mg/dL;
•Subjects with a history of eating disorders like anorexia nervosa or bulimia nervosa
•Subjects on prescription and non-prescription appetite or weight modifying drugs

Locations (15)

Pfizer Investigational Site

Clearwater, Florida, United States

Pfizer Investigational Site

Kissimmee, Florida, United States

Pfizer Investigational Site

Orlando, Florida, United States

Pfizer Investigational Site

Lexington, Kentucky, United States

Pfizer Investigational Site

Louisville, Kentucky, United States

Pfizer Investigational Site

Baton Rouge, Louisiana, United States

Pfizer Investigational Site

Milford, Massachusetts, United States

Pfizer Investigational Site

New York, New York, United States

Pfizer Investigational Site

Charlotte, North Carolina, United States

Pfizer Investigational Site

Nashville, Tennessee, United States

Key Dates

Start Date

March 1, 2005

Completion Date

November 1, 2005

Last Updated

August 12, 2009

Enrollment

282

ACTUAL participants

Conditions

Obesity

Interventions

CP-945,598

DRUG

sibutramine

DRUG

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 12, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss